Short answer
BridgeBio Pharma, Inc. (BBIO) filed an 8-K current report with the SEC on February 24, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q4 and full-year 2025 earnings reported February 24, 2026; period ended December 31, 2025.
BridgeBio Pharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 and full-year 2025 earnings reported February 24, 2026; period ended December 31, 2025
- Full financial details in Exhibit 99.1: press release contains key metrics and business updates
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other BridgeBio Pharma, Inc. 8-K filings
Get the next BBIO 8-K as it lands
Follow BBIO for push alerts, or ask the research agent what this filing means.